Share Repurchase Program Approved by Becton, Dickinson and Company (NYSE:BDX) Board

Becton, Dickinson and Company (NYSE:BDXGet Free Report) declared that its board has authorized a stock buyback program on Tuesday, January 28th, RTT News reports. The company plans to buyback 10,000,000 outstanding shares. This buyback authorization allows the medical instruments supplier to purchase shares of its stock through open market purchases. Stock buyback programs are typically an indication that the company’s management believes its stock is undervalued.

Analyst Ratings Changes

BDX has been the subject of a number of research reports. Piper Sandler increased their target price on Becton, Dickinson and Company from $275.00 to $280.00 and gave the stock an “overweight” rating in a research note on Tuesday. StockNews.com downgraded shares of Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a report on Wednesday, December 18th. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $283.00.

Get Our Latest Research Report on Becton, Dickinson and Company

Becton, Dickinson and Company Stock Up 0.6 %

Shares of BDX opened at $248.34 on Friday. The stock’s 50-day moving average price is $229.59 and its two-hundred day moving average price is $233.55. Becton, Dickinson and Company has a 12 month low of $218.75 and a 12 month high of $250.91. The company has a market capitalization of $72.02 billion, a PE ratio of 41.81, a PEG ratio of 1.72 and a beta of 0.39. The company has a current ratio of 1.17, a quick ratio of 0.74 and a debt-to-equity ratio of 0.69.

Becton, Dickinson and Company (NYSE:BDXGet Free Report) last released its earnings results on Thursday, November 7th. The medical instruments supplier reported $3.81 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.77 by $0.04. The company had revenue of $5.44 billion for the quarter, compared to the consensus estimate of $5.38 billion. Becton, Dickinson and Company had a net margin of 8.55% and a return on equity of 14.89%. Becton, Dickinson and Company’s quarterly revenue was up 6.9% compared to the same quarter last year. During the same quarter in the previous year, the company earned $3.42 EPS. On average, analysts anticipate that Becton, Dickinson and Company will post 14.42 EPS for the current year.

Becton, Dickinson and Company Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, March 31st. Investors of record on Monday, March 10th will be issued a $1.04 dividend. The ex-dividend date is Monday, March 10th. This represents a $4.16 dividend on an annualized basis and a dividend yield of 1.68%. Becton, Dickinson and Company’s dividend payout ratio is presently 70.03%.

Insider Activity

In other Becton, Dickinson and Company news, EVP Roland Goette sold 4,483 shares of the firm’s stock in a transaction on Friday, December 6th. The stock was sold at an average price of $221.01, for a total value of $990,787.83. Following the completion of the sale, the executive vice president now directly owns 24,345 shares of the company’s stock, valued at $5,380,488.45. This trade represents a 15.55 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, EVP David Shan sold 500 shares of the business’s stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $240.00, for a total value of $120,000.00. Following the completion of the sale, the executive vice president now owns 5,741 shares in the company, valued at $1,377,840. This represents a 8.01 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 9,844 shares of company stock worth $2,210,716 over the last 90 days. 0.36% of the stock is currently owned by corporate insiders.

Becton, Dickinson and Company Company Profile

(Get Free Report)

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.

Recommended Stories

Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.